Accelerating Medicines Partnership: Parkinson's Disease. Genetic Resource

• Published in: Movement disorders Vol. 36; no. 8; pp. 1795 - 1804
• Main Authors: Iwaki, Hirotaka, Leonard, Hampton L., Makarious, Mary B., Bookman, Matt, Landin, Barry, Vismer, David, Casey, Bradford, Gibbs, J. Raphael, Hernandez, Dena G., Blauwendraat, Cornelis, Vitale, Daniel, Song, Yeajin, Kumar, Dinesh, Dalgard, Clifton L., Sadeghi, Mahdiar, Dong, Xianjun, Misquitta, Leonie, Scholz, Sonja W., Scherzer, Clemens R., Nalls, Mike A., Biswas, Shameek, Singleton, Andrew B.
• Format: Journal Article
• Language: English
• Published: Hoboken, USA John Wiley & Sons, Inc 01.08.2021; Wiley Subscription Services, Inc
• Subjects: clinical; Cohort Studies; genetics; Genomes; Genotyping; Humans; LRRK2 protein; Movement disorders; Mutation; Neurodegenerative diseases; open science; Parkinson Disease - drug therapy; Parkinson Disease - genetics; Parkinson's disease; Polygenic inheritance; Population studies; Regular Issue; Whole genome sequencing; United States > US; open science; clinical; Parkinson's disease; genetics
• ISSN: 0885-3185; 1531-8257; 1531-8257
• DOI: 10.1002/mds.28549

Background Whole‐genome sequencing data are available from several large studies across a variety of diseases and traits. However, massive storage and computation resources are required to use these data, and to achieve sufficient power for discoveries, harmonization of multiple cohorts is critical. Objectives The Accelerating Medicines Partnership Parkinson's Disease program has developed a research platform for Parkinson's disease (PD) that integrates the storage and analysis of whole‐genome sequencing data, RNA expression data, and clinical data, harmonized across multiple cohort studies. Methods The version 1 release contains whole‐genome sequencing data derived from 3941 participants from 4 cohorts. Samples underwent joint genotyping by the TOPMed Freeze 9 Variant Calling Pipeline. We performed descriptive analyses of these whole‐genome sequencing data using the Accelerating Medicines Partnership Parkinson's Disease platform. Results The clinical diagnosis of participants in version 1 release includes 2005 idiopathic PD patients, 963 healthy controls, 64 prodromal subjects, 62 clinically diagnosed PD subjects without evidence of dopamine deficit, and 705 participants of genetically enriched cohorts carrying PD risk‐associated GBA variants or LRRK2 variants, of whom 304 were affected. We did not observe significant enrichment of pathogenic variants in the idiopathic PD group, but the polygenic risk score was higher in PD both in nongenetically enriched cohorts and genetically enriched cohorts. The population analysis showed a correlation between genetically enriched cohorts and Ashkenazi Jewish ancestry. Conclusions We describe the genetic component of the Accelerating Medicines Partnership Parkinson's Disease platform, a solution to democratize data access and analysis for the PD research community. © 2021 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society. This article is a U.S. Government work and is in the public domain in the USA.